Jun 18, 2026 08:00AM
Jun 18, 2026 08:00AM
May 15, 2026 04:30PM
May 5, 2026 08:00AM
May 5, 2026 08:00AM
Apr 27, 2026 08:00AM
Apr 27, 2026 08:00AM Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Apr 21, 2026 08:02AM
Apr 21, 2026 08:00AM
Mar 31, 2026 08:00AM
Mar 31, 2026 08:00AM
Mar 6, 2026 08:01AM
Mar 6, 2026 08:00AM
Mar 6, 2026 08:00AM Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
Mar 6, 2026 08:00AM
Feb 18, 2026 08:15AM
Feb 18, 2026 08:15AM
Feb 3, 2026 08:00AM
Feb 3, 2026 08:00AM
Dec 31, 2025 08:00AM
Nov 14, 2025 09:00AM Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
Sep 22, 2025 08:01AM
Sep 22, 2025 08:00AM
Aug 26, 2025 08:00AM
Aug 26, 2025 08:00AM
Jun 2, 2025 08:00AM
Jun 2, 2025 08:00AM
May 9, 2025 04:05PM Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
Apr 25, 2025 08:01AM
Apr 25, 2025 08:00AM
Mar 31, 2025 04:05PM
Mar 13, 2025 08:33AM
Mar 13, 2025 08:30AM
Mar 6, 2025 08:00AM
Feb 24, 2025 08:00AM Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Feb 6, 2025 08:01AM
Feb 6, 2025 08:00AM
Jan 30, 2025 08:06AM
Jan 30, 2025 08:00AM
Nov 18, 2024 08:03AM
Nov 18, 2024 08:00AM
Nov 14, 2024 08:00AM Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
Oct 18, 2024 12:47PM
Jul 22, 2024 06:32AM
Jul 22, 2024 06:30AM
Jun 25, 2024 08:00AM
May 14, 2024 04:01PM
May 2, 2024 08:03AM
May 2, 2024 08:00AM Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Dec 5, 2023 07:31AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All